WCG Wealth Advisors LLC Invests $574,000 in CRISPR Therapeutics AG $CRSP

WCG Wealth Advisors LLC purchased a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 10,937 shares of the company’s stock, valued at approximately $574,000.

Other large investors have also made changes to their positions in the company. JPMorgan Chase & Co. increased its position in shares of CRISPR Therapeutics by 98.3% during the third quarter. JPMorgan Chase & Co. now owns 593,416 shares of the company’s stock worth $38,459,000 after purchasing an additional 294,222 shares in the last quarter. O Neil Global Advisors Inc. acquired a new position in shares of CRISPR Therapeutics during the third quarter worth $10,934,000. UBS Group AG increased its position in shares of CRISPR Therapeutics by 7.7% in the 4th quarter. UBS Group AG now owns 2,524,144 shares of the company’s stock valued at $132,366,000 after acquiring an additional 180,580 shares during the period. SR One Capital Management LP increased its position in shares of CRISPR Therapeutics by 94.4% in the 3rd quarter. SR One Capital Management LP now owns 2,038,763 shares of the company’s stock valued at $132,132,000 after acquiring an additional 989,812 shares during the period. Finally, Clough Capital Partners L P acquired a new position in shares of CRISPR Therapeutics in the 3rd quarter valued at $1,491,000. 69.20% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 10,020 shares of the company’s stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $46.78, for a total value of $468,735.60. Following the sale, the chief executive officer directly owned 255,501 shares of the company’s stock, valued at approximately $11,952,336.78. This represents a 3.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Naimish Patel sold 3,786 shares of the company’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $55.62, for a total transaction of $210,577.32. Following the completion of the sale, the insider directly owned 19,357 shares in the company, valued at approximately $1,076,636.34. The trade was a 16.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 46,535 shares of company stock valued at $2,311,300. 4.30% of the stock is owned by insiders.

CRISPR Therapeutics Price Performance

NASDAQ:CRSP opened at $51.84 on Friday. CRISPR Therapeutics AG has a one year low of $39.58 and a one year high of $78.48. The company has a debt-to-equity ratio of 0.32, a quick ratio of 17.96 and a current ratio of 17.97. The firm has a market cap of $5.00 billion, a price-to-earnings ratio of -8.33 and a beta of 1.74. The firm’s fifty day moving average is $52.03 and its two-hundred day moving average is $53.14.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Tuesday, March 31st. The company reported ($1.28) EPS for the quarter. CRISPR Therapeutics had a negative net margin of 13,856.54% and a negative return on equity of 25.66%. The business had revenue of $1.46 million during the quarter. Research analysts expect that CRISPR Therapeutics AG will post -4.92 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Chardan Capital upped their target price on CRISPR Therapeutics from $74.00 to $76.00 and gave the company a “buy” rating in a research report on Saturday, February 14th. Wall Street Zen raised CRISPR Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Evercore reissued an “outperform” rating and issued a $76.00 target price on shares of CRISPR Therapeutics in a research report on Monday, May 11th. Citigroup reissued a “market outperform” rating on shares of CRISPR Therapeutics in a research report on Wednesday, May 27th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of CRISPR Therapeutics in a research report on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $65.47.

CRISPR Therapeutics Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent ?-thalassemia in collaboration with Vertex Pharmaceuticals.